发明名称 METHOD FOR TREATING CANCER HARBORING EGFR MUTATIONS
摘要 The present invention relates to a method of treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and/or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effect ive amount of the irreversible EGFR inhibitor BIBW2992 (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, and to the use of a BIBW 2992 (1) for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour.
申请公布号 KR20090074202(A) 申请公布日期 2009.07.06
申请号 KR20097007757 申请日期 2007.09.14
申请人 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 发明人 SOLCA FLAVIO
分类号 A61K31/517;A61K33/24;A61K39/395;A61P35/00 主分类号 A61K31/517
代理机构 代理人
主权项
地址